drugset / Trial / NCT05574881
Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy and safety of Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR+/HER2+ Metastatic Breast Cancer
Timeline
- Start
- 2022-09-01
- Primary completion
- 2025-01-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | 150 mg | — |
| Subject | Fulvestrant | Small molecule | 500 mg | — |
| Subject | Pertuzumab | Monoclonal antibody | 420 mg | — |
| Subject | Trastuzumab | Monoclonal antibody | 6 mg/kg | — |